Psychedelics are following cannabis into the mainstream of medicine, with Texas and Connecticut enacting laws this month allowing research into how psilocybin, the active ingredient in “magic mushrooms” might help people with post-traumatic stress disorder.
Gov. Greg Abbott (R-Texas) on June 18 allowed a bill (H.B. 1802) authorizing the study of psilocybin to become law without his signature. Connecticut Gov. Ned Lamott (D) on June 7 signed a bill (S.B. 1083) permitting psilocybin research in that state.
Oregon voters last year legalized psychedelics in licensed, supervised facilities, though treatment can’t take place until 2023, pending the development of regulations.
New “psychedelic-assisted therapies show tremendous promise” for treating illnesses that are resistant to other drugs, said Walter Greenleaf, a Stanford University neuroscientist and a medical technology developer.
Even before Connecticut and Texas acted, investors had taken notice of the pharmaceutical possibilities. At least three companies listed on U.S. stock exchanges have been touting psychedelics for the treatment of mental health disorders.